$1.2M Pradaxa Verdict For Plaintiffs
A West Virginia jury returned a $250,000 compensatory verdict along with awarding $1,000,000 more in punitive damages to plaintiffs injured by the blood thinner Pradaxa. Since October 2010, the German drug company Boehringer Ingelheim has sold Pradaxa in the United States. The company claims that the drug has achieved “blockbuster” status. This means it has over
Read More
Michael Lynch to Give Pradaxa Update at Mass Tort Nexus Conference
In Fort Lauderdale, FL, on March 11, Attorney Michel Brady Lynch, Esq. of The Michael Brady Lynch Firm in Winter Park will inform attorneys from around the country on the newest developments in the Pradaxa litigation. Attorney Michael Brady Lynch’s lecture is part of an intense 4-Day Immersion Course sponsored by Mass Tort Nexus. During
Read MoreAttorney Michael Brady Lynch Appointed to Plaintiff’s Executive Committee in Pradaxa Litigation
On November 18, 2016, Judge Mary Wiss appointed Michael Brady Lynch, Lead Trial attorney and founder of The Michael Brady Lynch Firm to serve on the Plaintiff’s Executive Committee (PEC) in Pradaxa litigation JCCP 4863. Attorneys across the country have continually asked Attorney Michael Brady Lynch to step into leadership positions for many litigations. Lynch
Read More
Momentum Builds in California Pradaxa Suits
Along with the other dedicated attorneys at The Michael Brady Lynch Firm, I have been leading the charge against the dangerous anticoagulant medication Pradaxa. We have been filing new cases for those that did not or could not participate in the MDL settlement. We are spearheading new litigations in Connecticut and Illinois. However, Californians should
Read More
Praxbind: A Band-Aid for Pradaxa’s Bleeding Epidemic
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. FDA and Pradaxa manufacturer, Boehringer Ingelheim are scrambling to rectify a huge mistake when Pradaxa the FDA agreed to fast-track the drug. Faulty studies and negligent marketing labeled Pradaxa as the safest and most effective blood thinner on the market. Now,
Read More
The Michael Brady Lynch Firm Spearheads New Pradaxa Bleeding Lawsuits
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. There is a sad misconception that those victims of uncontrollable Pradaxa bleeding who did not participate in the 2014 global settlement, or those who suffered uncontrollable bleeds after the settlement was announced, are somehow unable to pursue claims for their injuries. Nothing
Read MorePradaxa: A Case Study In A Broken FDA Approval System
The FDA Failed Pradaxa Users. This is attorney Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. The deeper one delves into the tragic history of the prescription blood thinner Pradaxa, more troubling facts emerge concerning our drug approval process. And both the FDA and Pradaxa manufacturer Boehringer Ingelheim is to blame.
Read MoreNew Pradaxa Bleeding Data Is Nothing Short of Terrifying
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. The latest data is out on Pradaxa bleeding events and the numbers are nothing short of downright terrifying. Pradaxa manufacturer Boehringer Ingelheim just put online on “pradaxa.de” some new data on fatal/major bleeds as reported to the company up to
Read MorePradaxa Bleeding Dangers and Conduct Reach New Highs and Lows
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Every day I am dismayed at the continued use of Pradaxa as a purported safe and effective alternative to warfarin for stroke prevention in patients with atrial fibrillation. In reality, Pradaxa has morphed into a national health disaster of uncontrollable bleeding.
Read MoreThe Michael Brady Lynch Firm Wins Remand of Pradaxa Case
Las Vegas: Today the law firms of Ed Bernstein & Associates, The Michael Brady Lynch Firm and Peiffer, Rosca, Abdullah & Carr announced the successful remand of a Las Vegas Pradaxa bleeding death case to Clark County, Nevada. By Order dated October 11, 2013, The Honorable David Herndon, who is overseeing Pradaxa MDL 2385 in
Read More